ANI Pharma (ANIP) Tops Q2 EPS by 34c; Boosts FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Guggenheim Raises Price Target on ANI Pharma (ANIP) Following 2Q Earnings Report
August 4, 2016 3:49 PM EDTGuggenheim reiterated a Buy rating on ANI Pharmaceuticals (NASDAQ: ANIP), and raised the price target to $80.00 (from $65.00), following the company's 2Q earnings report. ANIP reported adjusted diluted EPS of $1.11, $0.31 higher than consensus estimates. ANIP raised its '16 EPS guidance range from $3.54-$3.91 to... More
